Is DNA repair a potential target for effective therapies against malignant mesothelioma?

Ilaria Fuso Nerini, Elisa Roca, Laura Mannarino, Federica Grosso, Roberta Frapolli, Maurizio D'Incalci

Research output: Contribution to journalReview articlepeer-review


Malignant pleural mesothelioma (MPM) is a rare malignancy mainly caused by asbestos exposure. Germinal and acquired mutations in genes of DNA repair pathways, in particular of homologous recombination repair, are frequent in MPM. Here we overview the available experimental data suggesting that an impaired DNA repair system affects MPM pathogenesis by leaving lesions through the genome unresolved. DNA repair defects represent a vulnerability of MPM, and it seems plausible to propose that leveraging these deficiencies could have therapeutic potential for patients with MPM, for whom there is an urgent need of more effective therapies.

Original languageEnglish
Pages (from-to)102101
JournalCancer Treat. Rev.
Publication statusPublished - Nov 2020


  • Animals
  • Antineoplastic Combined Chemotherapy Protocols/pharmacology
  • Clinical Trials, Phase II as Topic
  • DNA Damage
  • DNA Repair
  • Humans
  • Mesothelioma, Malignant/drug therapy
  • Mutation
  • Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage
  • Randomized Controlled Trials as Topic


Dive into the research topics of 'Is DNA repair a potential target for effective therapies against malignant mesothelioma?'. Together they form a unique fingerprint.

Cite this